Indiana University

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Indiana University sits in the top decile of US sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count).

890 total trials 156 currently recruiting 561 completed top decile by trial count

Indiana University: 890 sponsored US clinical trials, 156 recruiting.

Indiana University sponsors 890 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 561 completed. 104 of these trials are in Phase 3-4 (later-stage) and 126 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Alzheimer Disease, with 11 trials.

Top-decile sponsor footprint

Indiana University ranks in the top decile of sponsors by registered trial count (#38 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 43/100

561 of 688 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

890 total, page 6 of 18

COMPLETED NA

Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment

NCT05618912

TERMINATED

Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors

NCT05611307

COMPLETED NA

Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes

NCT05577169

COMPLETED

Donors With Nephrolithiasis at the Time of Transplant Evaluation (DONATE). Long Term Follow-up.

NCT05519150

COMPLETED

Coronary Collaterals and Post-reperfusion Intramyocardial Hemorrhage

NCT05898425

COMPLETED NA

Renal Considerations in the Heat Stress Recommendations (Aim2)

NCT05458843

COMPLETED NA

Negative Pressure Wound Therapy-PICO: Cosmesis in Repeat C-Sections

NCT05266053

COMPLETED NA

Efficacy of COMET on Prolific Participants

NCT05379881

COMPLETED NA

Digital Detection of Dementia (D Cubed) Studies: D2

NCT05231954

COMPLETED Phase 2

Low-intensity Stepped Care for Internalizing Distress

NCT05441111

COMPLETED

AutoMated BUrn Diagnostic System for Healthcare (AMBUSH)

NCT05167461

TERMINATED

Serial Testing To Assess Cognitive Function In Cancer

NCT06160700

COMPLETED

Impact of EUS Guided Treatment of Gastric Varices

NCT05521685

COMPLETED NA

Neural Basis of Sensory and Motor Learning: Functional Connections

NCT05124301

COMPLETED NA

Academic-Community EPINET (AC-EPINET)

NCT04497857

COMPLETED NA

Comparison of Tissue Oxygenation Measurement Using Multimodal Devices

NCT05784103

COMPLETED Phase 2

Use of Aromatherapy to Reduce Symptom Burden

NCT05251337

COMPLETED NA

Nutritional Regulation of Leukocyte Function

NCT05191758

COMPLETED Phase 4

Buffered vs. Unbuffered Local Anesthesia in Mandibular Molars Diagnosed With Symptomatic Irreversible Pulpitis

NCT05227300

COMPLETED NA

Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB)

NCT06336681

TERMINATED Phase 1

ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery

NCT05257941

COMPLETED NA

The Effect of Intermittent Fasting on Acute Subconcussive Head Impacts

NCT05236127

TERMINATED Phase 2

Does Oxytocin Alter Tolerance to or Motivation for Alcohol

NCT05312008

TERMINATED NA

Gluteal Squeeze for Left Colon Distension

NCT04827485

COMPLETED

Menopause Racing Heart Study

NCT05062057

COMPLETED NA

Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study

NCT04616612

COMPLETED NA

PRIMA Intervention for Adults With Mild Cognitive Impairment and Their Caregivers

NCT04515875

COMPLETED NA

HIV-related Insomnia and Inflammation

NCT04721067

COMPLETED NA

Coconut Oil vs. Commercial Ultrasound Gel In Obstetric Ultrasounds

NCT05653362

COMPLETED Phase 1

Mirabegron and Physiological Function in Cold Environments

NCT04766021

TERMINATED NA

Non-invasive Vagus Nerve Stimulation in the Treatment of Crohn's Disease - A Pilot Study

NCT05165108

COMPLETED NA

Systematic Pediatric Assessment of Rome Criteria (SPARC)

NCT04773158

COMPLETED NA

Limb Health and Socket Pressure in Response to Powered Ankle Protheses

NCT05112679

COMPLETED Phase 2

Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder

NCT04884763

COMPLETED NA

The Effects of Whey Protein Supplements on Markers of Exercise-induced Muscle Damage in Resistance-trained Individuals

NCT05100459

TERMINATED NA

Frontal-Striatal Reward Circuit Neuromodulation and Alcohol Self-Administration

NCT04971681

COMPLETED Phase 1

Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets

NCT04199624

TERMINATED

Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting for Actively Smoking Family Members

NCT03966807

COMPLETED NA

Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease

NCT04520698

COMPLETED Phase 4

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788

COMPLETED NA

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

NCT05364450

COMPLETED NA

A Theory Driven, Rurally Tailored, Family-Based, Telehealth Intervention for Childhood Obesity

NCT04720703

TERMINATED NA

Healthy Volunteer Short Chain Fatty Acid Study

NCT05254340

COMPLETED Phase 4

Effect of Perioperative Gabapentin on Postoperative Opioid Requirements

NCT05494385

COMPLETED NA

The Effects of the Safe and Sound Protocol on PTSD Symptoms and Anxiety

NCT04999852

COMPLETED Phase 2

Suppressive Antibacterial Therapy With Once-Weekly Secnidazole Granules to Prevent Recurrent Bacterial Vaginosis; A Pilot Study

NCT05033743

COMPLETED NA

Sedline EEG Guided Depth of Anesthesia

NCT05051982

TERMINATED

Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)

NCT04930055

COMPLETED NA

Electroceutical Dressing Technology (EDT) Against Wound Microbial Biofilm Infection

NCT04794621

COMPLETED

HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy

NCT04798014

← Previous Page 6 of 18 Next →

Phase Distribution

PhaseTrial count
Phase 1 56
Phase 2 70
Phase 3 28
Phase 4 76

What is open in the Indiana University pipeline

156 recruiting of 890 indexed (18% open); 561 completed (63%).

Phase mix: 104 late (III/IV) vs 126 early (I/II) (balanced across stages).

Top condition: Alzheimer Disease (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Indiana University: open-pipeline peers nationwide

Peers matched on 890 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Indiana UniversityUniversity of California, Los AngelesHoffmann-La RocheBrigham and Women's HospitalUniversity of Texas Southwestern Medical CenterEdwards LifesciencesUniversity of South FloridaVA Office of Research and DevelopmentConvaTec
Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Indiana University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 890 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Indiana University page

890 registered trials is a research-attention snapshot, not an endorsement of Indiana University or any single study.

  • 156 of Indiana University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Alzheimer Disease is the condition Indiana University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Alzheimer Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Indiana University pipeline card: 890 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.